120 related articles for article (PubMed ID: 29299751)
21. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer.
Soubeyran P; Fonck M; Blanc-Bisson C; Blanc JF; Ceccaldi J; Mertens C; Imbert Y; Cany L; Vogt L; Dauba J; Andriamampionona F; Houédé N; Floquet A; Chomy F; Brouste V; Ravaud A; Bellera C; Rainfray M
J Clin Oncol; 2012 May; 30(15):1829-34. PubMed ID: 22508806
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
Dorff TB; Tsao-Wei DD; Groshen S; Boswell W; Goldkorn A; Xiong S; Quinn DI; Pinski JK
Clin Genitourin Cancer; 2013 Dec; 11(4):416-22. PubMed ID: 24099865
[TBL] [Abstract][Full Text] [Related]
23. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
Conteduca V; Caffo O; Lolli C; Aieta M; Scarpi E; Bianchi E; Maines F; Schepisi G; Salvi S; Massari F; Carrozza F; Veccia A; Chiuri VE; Campadelli E; Facchini G; De Giorgi U
Prostate; 2017 Jun; 77(9):1012-1019. PubMed ID: 28429372
[TBL] [Abstract][Full Text] [Related]
24. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
Garcia JA; Elson P; Tyler A; Triozzi P; Dreicer R
Urol Oncol; 2014 Jan; 32(1):33.e11-7. PubMed ID: 23510862
[TBL] [Abstract][Full Text] [Related]
25. Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.
Ward P; Hecht JR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Naeim A
J Geriatr Oncol; 2014 Oct; 5(4):368-75. PubMed ID: 25002322
[TBL] [Abstract][Full Text] [Related]
26. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive geriatric assessment in Korean elderly cancer patients receiving chemotherapy.
Kim YJ; Kim JH; Park MS; Lee KW; Kim KI; Bang SM; Lee JS; Kim CH
J Cancer Res Clin Oncol; 2011 May; 137(5):839-47. PubMed ID: 20820804
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.
Park S; Hong J; Hwang I; Ahn JY; Cho EY; Park J; Cho EK; Shin DB; Lee JH
J Geriatr Oncol; 2015 Nov; 6(6):470-8. PubMed ID: 26522808
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial.
Eichler M; Singer S; Janni W; Harbeck N; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Scholz C; Fink V; Schwentner L
Breast Cancer; 2017 Mar; 24(2):319-325. PubMed ID: 27262301
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel in castration-resistant prostate cancer: a single-centre experience.
Detti B; Franceschini D; Saieva C; Di Brina L; Baki M; Meattini I; Di Cataldo V; Pasquetti EM; Furfaro I; Mancuso A; Simontacchi G; Livi L
Cancer Invest; 2014 Nov; 32(9):445-50. PubMed ID: 25259606
[TBL] [Abstract][Full Text] [Related]
31. Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.
Bonnet C; Boudou-Rouquette P; Azoulay-Rutman E; Huillard O; Golmard JL; Carton E; Noé G; Vidal M; Orvoen G; Chah Wakilian A; Villeminey C; Blanchet B; Alexandre J; Goldwasser F; Thomas-Schoemann A
Cancer Chemother Pharmacol; 2017 May; 79(5):1051-1055. PubMed ID: 28361167
[TBL] [Abstract][Full Text] [Related]
32. Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Joly F; Delva R; Mourey L; Sevin E; Bompas E; Vedrine L; Ravaud A; Eymard JC; Tubiana-Mathieu N; Linassier C; Houede N; Guillot A; Ringensen F; Cojocarasu O; Valenza B; Leconte A; Lheureux S; Clarisse B; Oudard S
BJU Int; 2015 Jan; 115(1):65-73. PubMed ID: 24180479
[TBL] [Abstract][Full Text] [Related]
33. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study.
Repetto L; Fratino L; Audisio RA; Venturino A; Gianni W; Vercelli M; Parodi S; Dal Lago D; Gioia F; Monfardini S; Aapro MS; Serraino D; Zagonel V
J Clin Oncol; 2002 Jan; 20(2):494-502. PubMed ID: 11786579
[TBL] [Abstract][Full Text] [Related]
35. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B
Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562
[TBL] [Abstract][Full Text] [Related]
36. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
[TBL] [Abstract][Full Text] [Related]
38. Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Miano ST; De Rubertis G; Barbanti G; Bianco V; Brozzetti S; Francini E
Med Oncol; 2015 Mar; 32(3):52. PubMed ID: 25636506
[TBL] [Abstract][Full Text] [Related]
39. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
[TBL] [Abstract][Full Text] [Related]
40. Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.
Falandry C; Brain E; Bonnefoy M; Mefti F; Jovenin N; Rigal O; Guillem O; El Kouri C; Uwer L; Abadie-Lacourtoisie S; Cretin J; Jacquin JP; Paraiso D; Freyer G
Eur J Cancer; 2013 Sep; 49(13):2806-14. PubMed ID: 23735702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
